Table 5. Joint-effects survival analysis of PLCE1 haplotypes and serum AFP levels in HBV-related HCC patients.
| Group | Haplotypes | AFP (ng/mL) | Patients (2n=842) | No. of events (%) | MST (months) | Crude HR(95% CI) | CrudeP | Adjusted HR(95% CI) | Adjusted P§ |
|---|---|---|---|---|---|---|---|---|---|
| I | AC | AFP <20 | 191 | 59 (30.9) | 75 | 1 | 1 | ||
| II | AC | AFP ≥20 | 456 | 224 (49.1) | 41 | 1.826 (1.370-2.433) | 0.00004 | 1.392 (1.034-1.873) | 0.029 |
| III | GT | AFP <20 | 47 | 21 (44.7) | 71 | 1.417 (0.861-2.332) | 0.170 | 1.539 (0.932-2.541) | 0.092 |
| IV | GT | AFP ≥20 | 148 | 70 (47.3) | 40 | 1.817 (1.285-2.571) | 0.001 | 1.445 (1.015-2.057) | 0.041 |
| A | AC | AFP <200 | 339 | 136 (40.1) | 61 | 1 | 1 | ||
| B | AC | AFP ≥200 | 308 | 147 (47.7) | 51 | 1.256 (0.994-1.586) | 0.056 | 0.961 (0.751-1.229) | 0.749 |
| C | GT | AFP <200 | 79 | 36 (45.6) | 51 | 1.124 (0.779-1.624) | 0.532 | 1.282 (0.885-1.858) | 0.189 |
| D | GT | AFP ≥200 | 116 | 55 (47.4) | 40 | 1.301 (0.951-1.780) | 0.100 | 1.034 (0.750-1.424) | 0.839 |
| 1 | AC | AFP <400 | 374 | 150 (40.1) | 61 | 1 | 1 | ||
| 2 | AC | AFP ≥400 | 273 | 133 (48.7) | 50 | 1.286 (1.017-1.624) | 0.035 | 1.007 (0.786-1.290) | 0.956 |
| 3 | GT | AFP <400 | 90 | 42 (46.7) | 51 | 1.128 (0.801-1.588) | 0.492 | 1.240 (0.876-1.754) | 0.225 |
| 4 | GT | AFP ≥400 | 105 | 49 (46.7) | 36 | 1.318 (0.954-1.821) | 0.094 | 1.077 (0.775-1.499) | 0.658 |
Notes: § Adjustment for Child–Pugh score, tumor size, tumor number, BCLC stage, radical resection, regional invasion, adjuvant antiviral treatment, PVTT in Cox proportional hazards regression model; MST, median survival time; HR, hazard ratio; CI, confidence interval.